CBD has low affinity for CB receptors. It acts as an antagonist or partial antagonist at endogenous cannabinoid receptors (each CB1 and CB2 receptor varieties along with other G-protein-coupled receptors [GPCRs]) by inhibiting entire binding of direct ligands, and may act principally at alloster